Revolution Medicines Reports Fourth Quarter and Year-End 2021 Financial Results and Update on Corporate Progress Portfolio News / By Karina Tin February 28, 2022
Plexium Announces $102M Financing to Advance Pipeline of Targeted Protein Degradation Therapies and Technology Platform Portfolio News / By Karina Tin February 23, 2022
Ribon Therapeutics, a Clinical Stage Biotechnology Company Targeting Stress Support Pathways in Cancer and Inflammation, Announces CEO Transition for Its Next Phase of Growth Portfolio News / By Karina Tin February 17, 2022
Kallyope Raises $236M Series D Financing to Fuel Expansion of Novel Gut-Brain Axis Therapeutic Programs Portfolio News / By Karina Tin February 15, 2022
NGM Bio’s NGM621 Receives Fast Track Designation from the FDA for the Treatment of Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration Portfolio News / By Karina Tin February 7, 2022
Plexium and Amgen Announce Multi-year, Drug Discovery Collaboration to Identify Novel Targeted Protein Degradation Therapies Portfolio News / By Karina Tin February 3, 2022
Synthekine Doses First Patient in Phase 1 Clinical Trial of IL-2 Partial Agonist, STK-012, for Treatment of Solid Tumors Portfolio News / By Karina Tin February 3, 2022
